Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis.

BMC pulmonary medicine - 23 Mar 2021

Barjaktarevic Igor, Miravitlles Marc

Abstract excerpt

Alpha-1 antitrypsin deficiency (AATD) is a significantly under-diagnosed genetic condition caused by reduced levels and/or functionality of alpha-1 antitrypsin (AAT), predisposing individuals to lung, liver or other systemic diseases. The management of individuals with the PI*MZ genotype, characterized by mild or moderate AAT deficiency, is less clear than of those with the most common severe deficiency genotype...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha 1-Antitrypsin
Share to alpha 1-Antitrypsin Deficiency

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genotype

Share to Practice Guidelines as Topic

Share to Pulmonary Disease, Chronic Obstructive

Source

Open in PubMed Open full text

Identifiers

PMID: 33757485
DOI: 10.1186/s12890-021-01466-x
PMCID: PMC7989144

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis.PMID 33757485Read ↗

Clinical considerations in individuals with α1-antitrypsin PI*SZ genotype.Semantic proximity Read ↗

α1-Antitrypsin deficiency and chronic respiratory disorders.Semantic proximity Read ↗

Diagnosing alpha-1 antitrypsin deficiency: the first step in precision medicineSemantic proximity Read ↗

A Review of α1-Antitrypsin DeficiencySemantic proximity Read ↗

COPD in individuals with the PiMZ alpha-1 antitrypsin genotype.Semantic proximity Read ↗

Alpha-1 antitrypsin deficiency: outstanding questions and future directionsSemantic proximity Read ↗

Comparison among populations with severe and intermediate alpha1-antitrypsin deficiency and chronic obstructive pulmonary disease.Semantic proximity Read ↗

Alpha-1 Antitrypsin Augmentation and the Liver Phenotype of Adults With Alpha-1 Antitrypsin Deficiency (Genotype Pi∗ZZ).Semantic proximity Read ↗

Alpha-1 antitrypsin deficiency: clarifying the role of the putative protective threshold.Semantic proximity Read ↗

Alpha-1 antitrypsin deficiency-associated liver disease: From understudied disorder to the poster child of genetic medicine.Semantic proximity Read ↗

Progression and Augmentation Therapy in PiSZ and PiZZ Alpha-1 Antitrypsin Deficiency: A Longitudinal Functional and Densitometric Study.Semantic proximity Read ↗

Rare alpha-1-antitrypsin variants: are they really so rare?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.